UK LEADER IN BREAKTHROUGH CANNABIS-BASED MEDICINES
Improving quality of life for patients
WHAT WE DO
GROW | EXTRACT | SELL
Licenced 100,000 sq ft
UK facility with indoor grow
and API extraction (EU-GMP)
CLINICAL TRIALS
UK’s only MHRA (conditionally) approved chronic pain trial using cannabis-based
medicines
OUR MISSION
Celadon’s mission is to improve quality of life for patients most in need by developing
breakthrough cannabis-based medicines
Celadon was founded in 2018 after cannabis-based medicinal products (CBMPs) were legalised in the UK.
Everything at Celadon starts with improving patients’ quality of life. Cannabis-based medicines have shown rapid growth internationally, with a growing evidence base for its role in treating a variety of conditions (e.g. epilepsy, multiple sclerosis, autism). Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in the UK, 50 million in the US, 100 million in Europe), with many problems with existing opioid treatments.
Celadon is uniquely positioned as a vertically integrated pharmaceutical company to deliver its patient-first mission.
The company has developed its licenced EU-GMP 100,000 sq ft UK facility to grow high-THC cannabis and extract to API for its medicines.
It has developed its MHRA conditionally approved chronic pain trial that has the potential to create a robust data set to support reimbursement on the National Health Service in the UK.
Celadon’s in-house R&D programme is focused on novel IP generation and its partnership with biopharma Kingdom Therapeutics is developing a licenced cannabinoid drug for Autism Spectrum Disorder.
OUR JOURNEY
In a market with significant regulatory and capital barriers to entry, Celadon is building the UK’s leading pharmaceutical cannabinoid company.
Celadon founded after medical cannabis legalisation in UK.
Celadon applies to UK regulators and MHRA, helping create the UK’s regulatory framework for cultivation and production.
Celadon successfully granted licence by UK regulators for legal cultivation of test batches of high THC cannabis.
Phase 1 of construction is completed at Celadon’s 100,000 sq ft UK facility, and first harvest is completed.
Acquisition of majority shareholding in LVL Health , which has the only MHRA conditionally approved chronic pain trial using cannabis based medicines.
Acquisition of minority stake in Kingdom Therapeutics, a UK leading biopharma developing a licensed cannabinoid treatment for autism spectrum disorder.
Phase 2 construction begins, which will take Celadon’s cultivation capacity to around 3 tonnes once complete.
Celadon completes in 7th harvest in the summer of 2022, to support its MHRA application for EU-GMP for its high-THC cannabinoid API.
LVL’s chronic pain trial enrols its first patients, with early results very promising for the reduction of pain (and opioid usage) and increasing sleep.
Celadon receives its GMP registration from the MHRA, following a successful site inspection.
First international shipment is approved to a U.S. DEA-licensed customer, establishing compliant export into the U.S. market.
Grant of the General Pharmaceutical Council (GPhC) licence supports regulated pharmaceutical supply and contributes to shorter patient waiting times in the UK.
Celadon granted updated licence by UK regulators allowing the commercial sale of its cannabis product.
BUILDING ON STRONG FOUNDATIONS
Discover more about our company, explore our achievements, and read the latest updates
WORKING WITH REGULATORS
Celadon is one of the first companies to receive EU-GMP approval by MHRA, and licenced by UK regulators to cultivate test batches of medicinal cannabis.
Celadon is one of a small number of companies globally to be awarded EU-GMP certification to manufacture high-THC cannabinoid active pharmaceutical ingredients (API); GMP allows Celadon to produce API for pharmaceutical prescription drugs and sell its product to the market.
Celadon’s chronic pain clinical trial (through LVL) has been conditionally approved by the UK’s MHRA. In contrast to observational studies, this Government-approved trial aims to provide a robust data set to support re-imbursement on the National Health Service.
